Economical aspect of biological therapy in inflammatory conditions in Hungary

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 327-337

  Laki, Judit ^a   Mónok, Gabriella ^a   Pálosi, Mihály ^a   Gajdácsi, József Zs ^a  

^a National Health Insurance Fund Administration OEP   (Hungary)

Author keywords

Biological therapy; Cost; Cost effective; Inflammation; Personalized therapy

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; HUNGARY; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; COST-BENEFIT ANALYSIS; HUMANS; HUNGARY; INFLAMMATION;

EID: 84873911390     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.735654     Document Type: Article

References (14)

1. Financing protocol of the diagnosis and treatment of rheumatoid arthritis. Hungarian National Health Insurance Fund Administration. 2010. Available from: http://site.oep.hu/steam/downloads/finprot/11-A-rheumatoid- arthritis- diagnosztikajanak-es-kezelesenek- finanszirozasi-protokollja.pdf
2. Financing protocol of the diagnosis and treatment of ankylosing spondylitis. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/13-A- spondylitis-ankylopoetica- diagnosztikajanak-es-kezelesenek- finanszirozasi-protokollja.pdf
3. Financing protocol of the diagnosis and treatment of psoriatic arthritis. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/14-Az-arthritis-psoriatica- diagnosztikajanak-es- kezelesenek-finanszirozasi-protokollja.pdf
4. Financing protocol of the diagnosis and treatment of juvenile idiopathic arthritis. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/12-A- juvenilis-idiopathias-arthritis- diagnosztikajanak-es-kezelesenek- finanszirozasi-protokollja.pdf
5. Financing protocol of the diagnosis and treatment of plaque psoriasis. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/10-A-plakkos- psoriasis- diagnosztikajanak-es- kezelesenek-finanszirozasi-protokollja.pdf
6. Financing protocol of the diagnosis and treatment of ulcerative colitis. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/09-A-colitis-ulcerosa- diagnosztikajanak-es-kezelesenek-finanszirozasi-protokollja.pdf
7. Financing protocol of the diagnosis and treatment of adult luminar Crohn's disease. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/07-A- felnottkori-Crohn-betegseg-diagnosztikajanak-es-kezelesenek-finanszirozasi- protokollja.pdf
8. Financing protocol of the diagnosis and treatment of adult fistulising Crohn's disease. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/08-A- felnottkori-fisztulazo-Crohn- betegseg-diagnosztikajanak- es-kezelesenek- finanszirozasi-protokollja. pdf
9. Financing protocol of the diagnosis and treatment of paediatric Crohn's disease. Hungarian National Health Insurance Fund Administration. 2010.Available from: http://site.oep.hu/steam/downloads/finprot/18-A-gyermekkori-Crohn- betegseg-diagnosztikajanak- es-kezelesenek-finanszirozasi-protokollja. pdf
10. Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biologic therapy. Rheumatology 2010;49:1197-9
11. Boers M. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al. Arthritis Rheum 2009;61:1616-17
12. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003
13. Tak PP. Understanding drug resistance to biologic therapy. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 2012;51:600-9
14. Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 4):iv21-6